T cells targeting an FLT3 mutation selectively eliminate clonally involved primary AML cells in vivo
Recurrent driver mutations in FMS-related receptor tyrosine kinase 3 (FLT3) occur in around one-third of patients with de novo acute myeloid leukemia (AML). Although most FLT3 mutations are secondary ...
Impact of Postoperative Radiotherapy on the Prognosis of Early-Stage (pT1-2N0M0) Oral Tongue Squamous Cell Carcinoma Adults with FLT3-ITD AML in first remission underwent HCT and were randomly ...
RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results